Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment

被引：0
|
作者：
Lu, S. [1 ]
Cheng, Y. [2 ]
Wu, L. [3 ]
Fang, J. [4 ]
Li, B. [5 ]
Han, L. [6 ]
Zhang, Y. [7 ]
Pan, H. [8 ]
Wang, Z. [4 ]
Sun, Y. [9 ]
Ye, F. [10 ]
Hu, Y. [11 ]
Yu, W. [12 ]
Zhou, H. [12 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
[2] Jilin Canc Hosp, Changchun, Peoples R China
[3] Hunan Canc Hosp, Affiliated Canc Hosp Xiangya Sch Med, Dept Thorac Oncol 2, Changsha, Peoples R China
[4] Peking Univ Canc Hosp, Beijing, Peoples R China
[5] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China
[6] Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China
[7] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[8] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Peoples R China
[9] Jinan Cent Hosp, Jinan, Peoples R China
[10] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
[11] Hubei Canc Hosp, Wuhan, Peoples R China
[12] Innovent Biol Inc, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
anti-VEGF antibody; anti-PD-1; antibody; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P79.08
引用
收藏
页码：S649 / S649
页数：1
相关论文
共 50 条
  • [1] VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
    Lu, S.
    Wu, L.
    Jian, H.
    Cheng, Y.
    Wang, Q.
    Fang, J.
    Wang, Z.
    Hu, Y.
    Sun, M.
    Han, L.
    Miao, L.
    Ding, C.
    Cui, J.
    Li, B.
    Li, X.
    Wang, K.
    Cang, S.
    Pan, Y.
    Ye, F.
    Liu, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (01) : 112 - 113
  • [2] The efficacy of chemotherapy in the advanced NSCLC patients who failed with the treatment of EGFR-TKI
    Zhou, S.
    Ren, S.
    Zhang, L.
    Sun, H.
    Zhou, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis
    Han, B.
    Tian, P.
    Zhao, Y.
    Yu, X.
    Guo, Q.
    Yu, Z.
    Zhang, X.
    Li, Y.
    Chen, L.
    Shi, X.
    Zhang, Y.
    Wang, J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1443 - S1444
  • [4] Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI
    Riess, J.
    Kelly, K.
    Schalper, K.
    Shimoda, M.
    Lim, S.
    Monjazeb, A.
    Danenberg, K.
    Moore, E.
    Beckett, L.
    Mack, P.
    Maverakis, E.
    Gandara, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S528 - S528
  • [5] Cytoplasmic ERβ expression to predict efficacy and survival of EGFR-TKI in EGFR-mutant NSCLC
    Wang, Zhijie
    Wang, Jie
    Wang, Xiaodong
    Shen, Zhirong
    Ding, Xiaosheng
    Bai, Hua
    Duan, Jianchun
    An, Tongtong
    Wang, Yuyan
    Zhuo, Minglei
    Wang, Shuhang
    Wu, Meina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Plasma microRNA signatures to predict EGFR-TKI resistance in EGFR-mutant advanced NSCLC patients.
    Wang, Shuhang
    Wang, Jie
    Bai, Hua
    An, Tongtong
    Zhao, Jun
    Wang, Zhijie
    Duan, Jianchun
    Zhuo, Minglei
    Wang, Yuyan
    Wu, Meina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
    Huang, Y. H.
    Hsu, K. -H.
    Tseng, J. -S.
    Chen, K. -C.
    Chang, G. -C.
    Yang, T. -Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S477 - S478
  • [8] Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
    He, Y.
    Zhao, C.
    Li, X.
    Ren, S.
    Jiang, T.
    Zhang, J.
    Su, C.
    Chen, X.
    Cai, W.
    Gao, G.
    Li, W.
    Wu, F.
    Li, J.
    Zhao, J.
    Zhou, F.
    Hu, Q.
    Hirsch, F. R.
    Zhou, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1970 - S1970
  • [9] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    [J]. Journal of Translational Medicine, 17
  • [10] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
12345